Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention

Circulation

Volumn 120, Issue 18, 2009, Pages 1793-1799

  Spargias, Konstantinos ^a   Adreanides, Elias ^a   Demerouti, Eftihia ^a   Gkouziouta, Angeliki ^a   Manginas, Athanassios ^a   Pavlides, Gregory ^a   Voudris, Vassilis ^a   Cokkinos, Dennis V ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

Angiography; Contrast media; Iloprost; Prostaglandins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CONTRAST MEDIUM; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; LOOP DIURETIC AGENT; PLACEBO;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTRAST INDUCED NEPHROPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; ILOPROST; KIDNEY DISEASES; MALE; MIDDLE AGED; NEPHRITIS; PREMEDICATION; PROTECTIVE AGENTS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 70449449081     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.863159     Document Type: Article

References (40)

1. Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362:598-603.
2. Berns AS. Nephrotoxicity of contrast media. Kidney Int. 1989;36: 730-740.
3. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, Berger PB. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2002;39:1113-1119.
4. Gruberg L, Mintz GS, Mehran R, Dangas G, Lansky AJ, Kent KM, Pichard AD, Satler LF, Leon MB. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36:1542-1548.
5. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368-375.
6. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259-2264.
7. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331:1416-1420.
8. Maeder M, Klein M, Fehr T, Rickli H. Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol. 2004;44:1763-1771.
9. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008;51:1419-1428.
10. Brezis M, Rosen S. Hypoxia of the renal medulla: its implications for disease. N Engl J Med. 1995;332:647-655.
11. Schlondorff D. Renal prostaglandin synthesis: sites of production and specific actions of prostaglandins. Am J Med. 1986;81:1-11.
12. Heyman SN, Rosen S, Brezis M. Radiocontrast nephropathy: a paradigm for the synergism between toxic and hypoxic insults in the kidney. Exp Nephrol. 1994;2:153-157.
13. Krause W, Muschick P, Kruger U. Use of near-infrared reflection spec-troscopy to study the effects of X-ray contrast media on renal tolerance in rats: effects of a prostacyclin analogue and of phosphodiesterase inhibitors. Invest Radiol. 2002;37:698-705.
14. Paller MS, Manivel JC. Prostaglandins protect kidneys against ischemic and toxic injury by a cellular effect. Kidney Int. 1992;42:1345-1354.
15. Itoh Y, Yano T, Sendo T, Oishi R. Clinical and experimental evidence for prevention of acute renal failure induced by radiographic contrast media. J Pharmacol Sci. 2005;97:473-488.
16. Yano T, Itoh Y, Kubota T, Sendo T, Oishi R. A prostacyclin analog beraprost sodium attenuates radiocontrast media-induced LLC-PK1 cells injury. Kidney Int. 2004;65:1654-1663.
17. Spargias K, Adreanides E, Giamouzis G, Karagiannis S, Gouziouta A, Manginas A, Voudris V, Pavlides G, Cokkinos DV. Iloprost for prevention of contrast-mediated nephropathy in high-risk patients undergoing a coronary procedure: results of a randomized pilot study. Eur J Clin Pharmacol. 2006;62:589-595.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creat-inine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
19. Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, Voudris V, Pavlides G, Buller CE, Kremastinos D, Cokkinos DV. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004;110:2837-2842.
20. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percuta-neous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393-1399.
21. Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE, Gelormini JL, Labinaz M, Moreyra AE, for the Investigators of the CARE Study. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007;115:3189-3196.
22. Staniloae CS, Doucet S, Sharma SK, Katholi RE, Mody KR, Coppola JT, Solomon R. N-acetylcysteine added to volume expansion with sodium bicarbonate does not further prevent contrast-induced nephropathy: results from the Cardiac Angiography in Renally Impaired Patients Study. J Interv Cardiol. 2009;22:261-265.
23. Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, Ree M, Shah AI, Burchette RJ. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA. 2008;300: 1038-1046.
24. Maioli M, Toso A, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, Bellandi F. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol. 2008;52:599-604.
25. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, Steen VD, Varga J, Jimenez S, Mayes M, Clements PJ, Weiner SR, Porter J, Ellman M, Wise C, Kaufman LD, Williams J, Dole W. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Ann Intern Med. 1994;120:199-206.
26. Moncada S, Vane JR. Prostacyclin and blood coagulation. Drugs. 1981; 21:430-437. (Pubitemid 12181705)
27. Zusman RM, Crow JW, Cato AE, Tolkoff-Rubin N. Effects of prosta-cyclin infusion in uremic patients: hematologic and hemodynamic responses. Clin Pharmacol Ther. 1981;30:251-257.
28. Sketch MH Jr, Whelton A, Schollmayer E, Koch JA, Bernink PJ, Wol-tering F, Brinker J, for the Prostaglandin E1 Study Group. Prevention of contrast media-induced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo-controlled study. Am J Ther. 2001;8: 155-162.
29. Rudnick MR, Goldfarb S. Pathogenesis of contrast-induced nephropathy: experimental and clinical observations with an emphasis on the role of osmolality. Rev Cardiovasc Med. 2003;4:S28-S33.
30. Zagler A, Azadpour M, Mercado C, Hennekens CH. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J. 2006;151:140-145.
31. Briguori C, Airoldi F, D'Andrea D, Bonizzoni E, Morici N, Focaccio A, Michev I, Montorfano M, Carlino M, Cosgrave J, Ricciardelli B, Colombo A. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007;115:1211-1217.
32. Heller R, Werner-Felmayer G, Werner ER. Antioxidants and endothelial nitric oxide synthesis. Eur J Clin Pharmacol. 2006;62:21-28.
33. Workman RJ, Shaff MI, Jackson RV, Diggs J, Frazer MG, Briscoe C. Relationship of renal hemodynamic and functional changes following intravascular contrast to the renin-angiotensin system and renal prosta-cyclin in the dog. Invest Radiol. 1983;18:160-166.
34. Turker RK, Demirel E, Ercan ZS. Iloprost preserves kidney function against anoxia. Prostaglandins Leukot Essent Fatty Acids. 1988;31: 45-52.
35. Agmon Y, Peleg H, Greenfeld Z, Rosen S, Brezis M. Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest. 1994;94:1069-1075.
36. Yano T, Itoh Y, Kubota T, Sendo T, Koyama T, Fujita T, Saeki K, Yuo A, Oishi R. A prostacyclin analog prevents radiocontrast nephropathy via phosphorylation of cyclic AMP response element binding protein. Am J Pathol. 2005;166:1333-1342.
37. Boie Y, Rushmore TH, Darmon-Goodwin A, Grygorczyk R, Slipetz DM, Metters KM, Abramovitz M. Cloning and expression of a cDNA for the human prostanoid IP receptor. J Biol Chem. 1994;269:12173-12178. (Pubitemid 24196718)
38. Fujita T, Fuke Y, Satomura A, Hidaka M, Ohsawa I, Endo M, Komatsu K, Ohi H. PGl2 analogue mitigates the progression rate of renal dysfunction improving renal blood flow without glomerular hyperfiltration in patients with chronic renal insufficiency. Prostaglandins Leukot Essent Fatty Acids. 2001;65:223-227.
39. Morgera S, Woydt R, Kern H, Schmutzler M, DeJonge K, Lun A, Rohde W, Konertz W, Kox WJ, Neumayer HH. Low-dose prostacyclin preserves renal function in high-risk patients after coronary bypass surgery. Crit Care Med. 2002;30:107-112.
40. Poggio ED, Nef PC, Wang X, Greene T, Van Lente F, Dennis VW, Hall PM. Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. Am J Kidney Dis. 2005;46:242-252. (Pubitemid 41040352)